Study | No. Of patients | No. Vertebral bodies | Treated levels | Age | Injected volume | Success | PreopVAS | PostopVAS | Asymptomaticleakage 6 2 | Complications | FU |
---|---|---|---|---|---|---|---|---|---|---|---|
Mont'Alverne et al., 2005 | 12 | 12 | C2 | 52.3 | 2.7 | 80% | - | - | 6 | 1 occipitalneuralgia, 1 stroke; | 6.9 |
Pflugmacher etal., 2006 | 3 | 12 | C3 – C7 | 60.4 | 1.8 | - | 6.3 | 2.9 | 2 | None | 12 |
Sun et al., 2010 | 10 | 10 | C2,others | 62.1 | 3 | 100% | - | - | 4 | 3 cases of mild odynophagia | 10.7 |
Masala et al.,2011 | 62 | 70 | C1 – C7 | 61.5 | 2.5 | 97% | 7.9 | 1.7 | 2 | None | 3 |
Anselmetti et al.,2012 | 25 | 25 | C2 | 59.3 | - | 80% | 8.1 | 1.0 | 6 | None | 21.8 |
Blondel et al.,2012 | 6 | 6 | C2 – C5 | 63.5 | - | - | 8.0 | 2.0 | 2 | None | 10 |
Total | 120 | 135 | 59.9 ± 4.0 | 2.5 ± 0.5 | 89% | 7.6 ± 0.9 | 1.9 ± 0.8 | 22 (16%; 95% CI,9.8 – 22.2) | 5 (4%; 95% CI, 0.5– 7.5%) | 10.7 ± 6.3 |
Success was defined as being pain-free or experiencing a statistically significant reduction in pain; VAS: visual analog scale; FU: follow-up.